Block listing Interim Review

GSK PLC
15 November 2023
 


BLOCK LISTING SIX MONTHLY RETURN

 

 

Date: 15 November 2023

 

Name of applicant:

GSK plc

Name of scheme:

GlaxoSmithKline plc 2017 Deferred Annual Bonus Plan

Period of return:

From:

1 May 2023  

To:

31 October 2023

Balance of unallotted securities under scheme(s) from previous return:

271,307

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

0

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

271,307

 

 

Name of applicant:

GSK plc

Name of scheme:

GlaxoSmithKline plc Share Save Plan 2012

Period of return:

From:

1 May 2023 

To:

31 October 2023

Balance of unallotted securities under scheme(s) from previous return:

558,829

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

52,231

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

506,598

 

 

Name of applicant:

GSK plc

Name of scheme:

GlaxoSmithKline plc Share Save Plan 2022

Period of return:

From:

1 May 2023 

To:

31 October 2023

Balance of unallotted securities under scheme(s) from previous return:

999,954

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

845

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

999,109

 

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

GSK (GSK)
UK 100
FTSE quotes by TradingView

Latest directors dealings

All directors dealings today